ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1716

TGFβ-Dependent Upregulation of XIAP Fosters Fibroblast Activation and Tissue Fibrosis By Promoting Canonical Wnt Signaling

Christina Bergmann1, Ludwig Hallenberger1, Amelie Brandt1, Benita Merlevede1, Clara Dees2, Chih-Wei Chen3, Christian Beyer1, Oliver Distler4, Georg Schett5 and Jörg Distler6, 1Department of Internal Medicine 3 and Institute for Clinical Immunology, Friedrich-Alexander-University of Erlangen-Nuremberg and University Hospital Erlangen, Erlangen, Germany, 2Department of Internal Medicine 3 and Institute for Clinical Immunology,, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany, 3Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, Erlangen, Germany, 4Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, 5Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Department of Internal Medicine 3 – Rheumatology and Immunology, Universitätsklinikum Erlangen, Erlangen, Germany., Erlangen, Germany, 6Department of Internal Medicine 3 – Rheumatology and Immunology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: fibroblasts and systemic sclerosis, WNT Signaling

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 6, 2017

Title: Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Pathogenesis, Animal Models and Genetics Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

Aberrant activation of profibrotic pathways is a key feature of systemic sclerosis (SSc). Extensive evidence characterizes TGFβ- and canonical WNT-signaling as key drivers of fibroblast activation. The crosstalk between those pathways, however, remains largely enigmatic. A better understanding of the interplay of different profibrotic pathways may be key to the development of effective targeted therapies.

XIAP (X-linked inhibitor of apoptosis protein) is an ubiquitously expressed member of the IAP protein family with important functions in tissue turnover and cell motility. XIAP was recently described as positive regulator of canonical Wnt signaling in embryogenesis. The aim of this study is to characterize the role of XIAP in fibrotic disease in SSc and to analyze the effects XIAP inhibition in vitro and in vivo.

Methods:

XIAP-expression was analyzed by qPCR, IF and Western blot. XIAP was targeted pharmacologically with Embelin. The activation of the canonical Wnt pathway was assessed by analyses of Wnt target genes and by TOPflash/FOPflash luciferase reporter assay. The interaction of XIAP with TLE3 was analyzed by co-immunoprecipitation. In vivo, XIAP inhibition was analyzed in three different models of fibrosis.

Results:

The expression of XIAP is increased in the skin of SSc patients compared to matched healthy individuals with a particularly prominent staining in fibroblasts. In addition, XIAP-expression is increased in experimental fibrosis models. The induction of XIAP in SSc in experimental fibrosis was mimicked by TGFβ in cultured fibroblasts. Moreover, targeted inhibition of TGFβ signaling prevented the induction of XIAP in experimental fibrosis. The upregulation of XIAP augmented the stimulatory effects of recombinant WNT proteins on fibroblasts. Inhibition of XIAP reduced the Wnt1-induced activation of normal dermal fibroblasts with reduced expression of myofibroblast markers and decreased collagen release. In addition, XIAP inhibition reverted the activated fibroblast phenotype in SSc fibroblasts. Inhibition of XIAP also demonstrated potent antifibrotic effects in experimental fibrosis in bleomycin-induced dermal fibrosis, in Topoisomerase-I-induced (TopoI) dermal and pulmonary fibrosis and in Wnt10b-transgenic mice. The inhibitory effects of Embelin on fibroblast activation were associated with impaired canonical WNT signaling with reduced TCF-dependent transcription in reporter assays and reduced levels of WNT target genes such as Axin2 in cultured fibroblasts and in fibrotic tissues. Mechanistically, we demonstrate that XIAP interacts with the endogenous antagonist TLE3 to regulate canonical WNT signaling.

Conclusion:

XIAP is upregulated in SSc fibroblasts in a TGFβ-dependent manner and promotes fibroblast activation by fostering canonical WNT signaling. XIAP thus serves to integrate TGFβ- and WNT signaling as two core pathways in SSc. XIAP-inhibition demonstrated antifibrotic effects in vitro and in vivo in non-toxic concentrations. Inhibition of XIAP may thus be a novel approach to target aberrant canonical WNT signaling in fibrotic diseases.


Disclosure: C. Bergmann, None; L. Hallenberger, None; A. Brandt, None; B. Merlevede, None; C. Dees, None; C. W. Chen, None; C. Beyer, None; O. Distler, 4 D Science, Actelion, Active Biotec, Bayer, Biogen Idec, Boehringer Ingelheim Pharma, BMS, ChemomAb, EpiPharm, Ergonex, espeRare foundation, GSK,Roche-Genentech, Inventiva, Lilly, medac, MedImmune, Mitsubishi Tanabe, Pharmacyclics, Pfizer, Sanofi, Seroda, 2; G. Schett, None; J. Distler, 4D Science, 1,Anamar Medical, Active Biotech, Array Biopma, BMS, Bayer Pharma, Boehringer Ingelheim, Celgene, GSK, Novartis, Sanofi-Aventis, UCB, 2,Actelion Pharmaceuticals US, Active Biotech, Anamar, Bayer Pharma, Boehringer Ingelheim, Celgene, Galapagos, GSK, Inventiva, JB Therapeutics, Medac, Pfizer, RuiYi, UCB, 5.

To cite this abstract in AMA style:

Bergmann C, Hallenberger L, Brandt A, Merlevede B, Dees C, Chen CW, Beyer C, Distler O, Schett G, Distler J. TGFβ-Dependent Upregulation of XIAP Fosters Fibroblast Activation and Tissue Fibrosis By Promoting Canonical Wnt Signaling [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/tgf%ce%b2-dependent-upregulation-of-xiap-fosters-fibroblast-activation-and-tissue-fibrosis-by-promoting-canonical-wnt-signaling/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/tgf%ce%b2-dependent-upregulation-of-xiap-fosters-fibroblast-activation-and-tissue-fibrosis-by-promoting-canonical-wnt-signaling/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology